Weiss Ratings Reaffirms Sell (D-) Rating for Astria Therapeutics (NASDAQ:ATXS)

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for Astria Therapeutics (NASDAQ: ATXS), indicating concerns about the stock's performance.
• Despite the sell rating from Weiss, other analysts have a more positive outlook, with price targets ranging from $20 to $49 and an average rating of "Moderate Buy."
• Astria Therapeutics' stock price has recently increased by 12.4%, trading at $8.40 with significant trading volume compared to its average.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other equities analysts have also recently issued reports about the stock. HC Wainwright boosted their price objective on shares of Astria Therapeutics from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, September 17th. Cantor Fitzgerald restated an "overweight" rating and issued a $49.00 target price on shares of Astria Therapeutics in a report on Wednesday, September 17th. Citigroup reaffirmed an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Evercore ISI reaffirmed an "outperform" rating and set a $26.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, October 1st. Finally, JMP Securities increased their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $29.50.

Astria Therapeutics Trading Up 12.4%

Astria Therapeutics stock traded up $0.93 during midday trading on Wednesday, hitting $8.40. 840,947 shares of the stock were exchanged, compared to its average volume of 366,786. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.52. The stock has a market capitalization of $474.10 million, a price-to-earnings ratio of -4.18 and a beta of 0.43. The stock's 50-day simple moving average is $7.01 and its 200 day simple moving average is $5.84.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04. Equities analysts anticipate that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. California State Teachers Retirement System increased its holdings in shares of Astria Therapeutics by 9.9% during the fourth quarter. California State Teachers Retirement System now owns 32,561 shares of the biotechnology company's stock valued at $291,000 after purchasing an additional 2,935 shares during the period. Sio Capital Management LLC grew its holdings in Astria Therapeutics by 1.0% during the second quarter. Sio Capital Management LLC now owns 318,256 shares of the biotechnology company's stock worth $1,706,000 after acquiring an additional 3,151 shares during the period. Farther Finance Advisors LLC grew its holdings in Astria Therapeutics by 185.8% during the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 3,557 shares during the period. American Century Companies Inc. grew its holdings in Astria Therapeutics by 8.3% during the second quarter. American Century Companies Inc. now owns 56,442 shares of the biotechnology company's stock worth $303,000 after acquiring an additional 4,335 shares during the period. Finally, Wellington Management Group LLP grew its holdings in Astria Therapeutics by 3.1% during the first quarter. Wellington Management Group LLP now owns 152,611 shares of the biotechnology company's stock worth $815,000 after acquiring an additional 4,562 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.